Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201706-06 Lead optimization of anti-cancer RNA oligonucleotide inducing immunogenic tumor death(Oncology, Genetics) [06.15.2018]

PRINT

Development and Market Objectives

Development of RNA-based anti-cancer drug that induces immunogenic apoptosis of a tumor by targeting retinoic acid-inducible gene I (RIG-I)

Unmet Medical Need & Target Patients

- Patients with cancers that can be treated by intratumoral injections. However, the indications can be expanded with further development on the targeted RNA delivery system.

- Current immunotherapy of cancer suffers from low response rates possibly due to heterogenetic nature of tumors. There is a growing list of pipelines that exploit novel mechanisms to activate tumor-targeted immunity.

Status

- Completed preliminary in vitro / in vivo efficacy test.

- Completed preliminary MOA of novel RIG-I agonist.

- Developed a platform to design the novel RIG-I agonists

Intellectual Property

Total 12 non-provisional patent applications in Korea, PCT, USA, and Europe.

Competitive Advantages

-    A novel pattern recognition molecular pattern (PAMP) for RIG-I that has not been reported elsewhere. 
-    Flexible chemical modifications lower the technical barriers in the development process of anti-cancer drugs.  

Indication

Solid Cancer

Research Period

2017.11.1-2018.10.31

Company

KAIST

Developmental Stage

Generation

Additional Information

Contact Information

Contact
Address Company Name: KAIST
WebSite Homepage: http:// Contact Person: ByongSeok Choi
E-mail: bschoi@kaist.ac.kr Contact: +82-42-350-2828

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code